Skip to main content
Erschienen in: Osteoporosis International 7/2008

01.07.2008 | Review

Leptin and the sympathetic connection of fat to bone

verfasst von: M. W. Hamrick, S. L. Ferrari

Erschienen in: Osteoporosis International | Ausgabe 7/2008

Einloggen, um Zugang zu erhalten

Abstract

Loss of body weight is associated with bone loss, and body weight gain is associated with increased bone formation. The molecular mechanisms linking body weight, body composition, and bone density are now better understood. Lean mass is likely to have a significant, local effect on bone modeling and remodeling through mechanotransduction pathways. In contrast to the local regulation of bone formation and resorption by muscle-derived stimuli, peripheral body fat appears to influence bone mass via secretion of systemic, endocrine factors that link body weight to bone density even in non-weight bearing regions (e.g., the forearm). The cytokine-like hormone leptin, which is secreted by fat cells, is an important candidate molecule linking changes in body composition with bone formation and bone resorption. Increases in body fat increase leptin levels and stimulate periosteal bone formation through its direct anabolic effects on osteoblasts, and through central (CNS) effects including the stimulation of the GH-IGF-1 axis and suppression of neuropeptide Y, a powerful inhibitor of bone formation. Stimulation of beta2-adrenergic receptors through central (hypothalamic) leptin receptors does, however, increase remodeling of trabecular bone, resulting in a lower cancellous bone volume that may be better adapted to a concomitantly larger cortical bone compartment. These findings suggest that body weight and body fat can regulate bone mass and structure through molecular pathways that are independent of load-bearing. Furthermore, pharmacological manipulation of the signaling pathways activated by leptin may have significant potential for the treatment and prevention of bone loss.
Literatur
1.
Zurück zum Zitat Rauch F, Bailey D, Baxter-Jones A et al (2004) The ‘muscle-bone unit’ during the pubertal growth spurt. Bone 34:771–775PubMedCrossRef Rauch F, Bailey D, Baxter-Jones A et al (2004) The ‘muscle-bone unit’ during the pubertal growth spurt. Bone 34:771–775PubMedCrossRef
2.
Zurück zum Zitat Greenlund LJ, Nair KS (2003) Sarcopenia-consequences, mechanisms, and potential therapies. Mech Ageing Dev 124:287–299PubMedCrossRef Greenlund LJ, Nair KS (2003) Sarcopenia-consequences, mechanisms, and potential therapies. Mech Ageing Dev 124:287–299PubMedCrossRef
3.
Zurück zum Zitat Huang R, Rubin C, McLeod K (1999) Changes in postural muscle dynamics as a function of age. J Gerontol A Biol Sci Med Sci 54:B352–357PubMed Huang R, Rubin C, McLeod K (1999) Changes in postural muscle dynamics as a function of age. J Gerontol A Biol Sci Med Sci 54:B352–357PubMed
4.
Zurück zum Zitat Eisman J (2001) Good, good, good...good vibrations: the best option for better bones? Lancet 358:1924–1925PubMedCrossRef Eisman J (2001) Good, good, good...good vibrations: the best option for better bones? Lancet 358:1924–1925PubMedCrossRef
5.
Zurück zum Zitat Schoenau E (2005) From mechanostat theory to development of the “Functional Muscle-Bone Unit”. J Musculoskelet Neuronal Interact 5:232–238PubMed Schoenau E (2005) From mechanostat theory to development of the “Functional Muscle-Bone Unit”. J Musculoskelet Neuronal Interact 5:232–238PubMed
6.
Zurück zum Zitat Qin Y, Lam H, Orzechowski L, Xia Y (2005) Bone fluid flow induced by skeletal muscle dynamics and its role in bone adaptation. J Bone Miner Res 20(Suppl 1):F185 Qin Y, Lam H, Orzechowski L, Xia Y (2005) Bone fluid flow induced by skeletal muscle dynamics and its role in bone adaptation. J Bone Miner Res 20(Suppl 1):F185
7.
Zurück zum Zitat Galvard H, Elmstahl S, Elmstahl B et al (1996) Differences in body composition between female geriatric hip fracture patients and healthy controls: body fat is more important as an explanatory factor for the fracture than body weight and lean body mass. Aging Clin Exp Res 8:282–286 Galvard H, Elmstahl S, Elmstahl B et al (1996) Differences in body composition between female geriatric hip fracture patients and healthy controls: body fat is more important as an explanatory factor for the fracture than body weight and lean body mass. Aging Clin Exp Res 8:282–286
8.
Zurück zum Zitat Reid I, Ames R, Evans M, Sharpe S, Gamble G, France J, Lim T, Cundy T (1992) Determinants of total body and regional bone mineral density in normal postmenopausal women-a key role for fat mass. J Clin Endocrinol Metab 75:45–51PubMedCrossRef Reid I, Ames R, Evans M, Sharpe S, Gamble G, France J, Lim T, Cundy T (1992) Determinants of total body and regional bone mineral density in normal postmenopausal women-a key role for fat mass. J Clin Endocrinol Metab 75:45–51PubMedCrossRef
9.
Zurück zum Zitat Fogelholm G, Sievänen H, Kukkonen-Harjula T, Pasanen M (2001) Bone mineral density during reduction, maintenance, and regain of body weight in premenopausal, obese women. Osteoporos Int 12:199–206PubMedCrossRef Fogelholm G, Sievänen H, Kukkonen-Harjula T, Pasanen M (2001) Bone mineral density during reduction, maintenance, and regain of body weight in premenopausal, obese women. Osteoporos Int 12:199–206PubMedCrossRef
10.
Zurück zum Zitat Grodin J, Siiteri P, MacDonald P (1973) Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 36:207–214PubMedCrossRef Grodin J, Siiteri P, MacDonald P (1973) Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 36:207–214PubMedCrossRef
11.
Zurück zum Zitat Reid I (2002) Relationships among body mass, its components, and bone. Bone 13:547–555CrossRef Reid I (2002) Relationships among body mass, its components, and bone. Bone 13:547–555CrossRef
12.
Zurück zum Zitat Berner H, Lyngstadaas S, Spahr A et al (2004) Adiponectin and its receptors are expressed in bone-forming cells. Bone 35:842–849PubMedCrossRef Berner H, Lyngstadaas S, Spahr A et al (2004) Adiponectin and its receptors are expressed in bone-forming cells. Bone 35:842–849PubMedCrossRef
13.
Zurück zum Zitat Jürimäe J, Jürimäe T (2007) Adiponectin is a predictor of bone mineral density in middle- aged premenopausal women. Osteoporos Int [Mar 30 ePub ahead of print] Jürimäe J, Jürimäe T (2007) Adiponectin is a predictor of bone mineral density in middle- aged premenopausal women. Osteoporos Int [Mar 30 ePub ahead of print]
14.
Zurück zum Zitat Reid I, Cornish J, Baldock P (2006) Nutrition-related peptides and bone homeostasis. J Bone Miner Res 21:495–500PubMedCrossRef Reid I, Cornish J, Baldock P (2006) Nutrition-related peptides and bone homeostasis. J Bone Miner Res 21:495–500PubMedCrossRef
15.
Zurück zum Zitat Hamrick MW (2007) Invited perspective: leptin and bone-a consensus emerging? BoneKey-Osteovision 4:99–107 Hamrick MW (2007) Invited perspective: leptin and bone-a consensus emerging? BoneKey-Osteovision 4:99–107
16.
Zurück zum Zitat Flier J (1998) What’s in a name? In search of leptin’s physiologic role. J Clin Endocrinol Metab 83:1407–1413PubMedCrossRef Flier J (1998) What’s in a name? In search of leptin’s physiologic role. J Clin Endocrinol Metab 83:1407–1413PubMedCrossRef
17.
Zurück zum Zitat Soyka L, Grinspoon S, Levitsky L et al (1999) The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab 84:4489–4496PubMedCrossRef Soyka L, Grinspoon S, Levitsky L et al (1999) The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab 84:4489–4496PubMedCrossRef
18.
19.
Zurück zum Zitat Frisch R, Revelle R (1970) Height and weight at menarche and a hypothesis of critical body weights and adolescent events. Science 169:397–399PubMedCrossRef Frisch R, Revelle R (1970) Height and weight at menarche and a hypothesis of critical body weights and adolescent events. Science 169:397–399PubMedCrossRef
20.
Zurück zum Zitat Matkovic V, Ilich J, Skugor M et al (1997) Leptin is inversely related to age at menarche in human females. J Clin Endocrinol Metab 82:3239–3245PubMedCrossRef Matkovic V, Ilich J, Skugor M et al (1997) Leptin is inversely related to age at menarche in human females. J Clin Endocrinol Metab 82:3239–3245PubMedCrossRef
21.
Zurück zum Zitat Rosenthal D, Mayo-Smith W, Hayes C et al (1989) Age and bone mass in premenopausal women. J Bone Miner Res 4:533–538PubMedCrossRef Rosenthal D, Mayo-Smith W, Hayes C et al (1989) Age and bone mass in premenopausal women. J Bone Miner Res 4:533–538PubMedCrossRef
22.
Zurück zum Zitat Bonjour J-P, Chevalley T (2007) Pubertal timing, peak bone mass and fragility fracture risk. BoneKEy-Osteovision 4:30–48 Bonjour J-P, Chevalley T (2007) Pubertal timing, peak bone mass and fragility fracture risk. BoneKEy-Osteovision 4:30–48
23.
Zurück zum Zitat Clark EM, Ness AR, Tobias JH (2006) Adipose tissue stimulates bone growth in prepubertal children. J Clin Endocrinol Metab 91:2534–2541PubMedCrossRef Clark EM, Ness AR, Tobias JH (2006) Adipose tissue stimulates bone growth in prepubertal children. J Clin Endocrinol Metab 91:2534–2541PubMedCrossRef
24.
Zurück zum Zitat Chehab F, Lim ME, Lu R (1996) Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet 12:318–320PubMedCrossRef Chehab F, Lim ME, Lu R (1996) Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet 12:318–320PubMedCrossRef
25.
Zurück zum Zitat Carro E, Senaris R, Considine R, Casanueva F, Dieguez C (1997) Regulation of in vivo growth hormone secretion by leptin. Endocrinology 138:2203–2206PubMedCrossRef Carro E, Senaris R, Considine R, Casanueva F, Dieguez C (1997) Regulation of in vivo growth hormone secretion by leptin. Endocrinology 138:2203–2206PubMedCrossRef
26.
Zurück zum Zitat Gat-Yablonski G, Ben-Ari T, Shaif B et al (2004) Leptin reverses the inhibitory effect of caloric restriction on longitudinal growth. Endocrinology 145:343–350PubMedCrossRef Gat-Yablonski G, Ben-Ari T, Shaif B et al (2004) Leptin reverses the inhibitory effect of caloric restriction on longitudinal growth. Endocrinology 145:343–350PubMedCrossRef
27.
Zurück zum Zitat Welt C, Chan J, Bullen J et al (2004) Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 351:987–997PubMedCrossRef Welt C, Chan J, Bullen J et al (2004) Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 351:987–997PubMedCrossRef
28.
Zurück zum Zitat Yamauchi M, Sugimoto T, Yamaguchi T, Nakaoka D, Kanzawa M, Yano S, Ozuru R, Sugishita T, Chihara K (2001) Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin Endocrinol 55:341–347CrossRef Yamauchi M, Sugimoto T, Yamaguchi T, Nakaoka D, Kanzawa M, Yano S, Ozuru R, Sugishita T, Chihara K (2001) Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin Endocrinol 55:341–347CrossRef
29.
Zurück zum Zitat Thomas T, Burguera B, Melton L et al (2001) Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 29:114–120PubMedCrossRef Thomas T, Burguera B, Melton L et al (2001) Role of serum leptin, insulin, and estrogen levels as potential mediators of the relationship between fat mass and bone mineral density in men versus women. Bone 29:114–120PubMedCrossRef
30.
Zurück zum Zitat Blain H, Vuillemin A, Guillemin F et al (2002) Serum leptin level is a predictor of bone mineral density in postmenopausal women. J Clin Endocrinol Metab 87:1030–1035PubMedCrossRef Blain H, Vuillemin A, Guillemin F et al (2002) Serum leptin level is a predictor of bone mineral density in postmenopausal women. J Clin Endocrinol Metab 87:1030–1035PubMedCrossRef
31.
Zurück zum Zitat Weiss L, Barrett-Connor E, von Muhlen D, Clark P (2006) Leptin predicts BMD and one resorption in older women but not older men: the Rancho-Bernardo study. J Bone Miner Res 21:758–764PubMedCrossRef Weiss L, Barrett-Connor E, von Muhlen D, Clark P (2006) Leptin predicts BMD and one resorption in older women but not older men: the Rancho-Bernardo study. J Bone Miner Res 21:758–764PubMedCrossRef
32.
Zurück zum Zitat Lorentzon M, Landin K, Mellström D, Ohlsson C (2006) Leptin is a negative independent predictor of areal BMD and cortical bone size in young adult Swedish men. J Bone Miner Res 21:1871–1878PubMedCrossRef Lorentzon M, Landin K, Mellström D, Ohlsson C (2006) Leptin is a negative independent predictor of areal BMD and cortical bone size in young adult Swedish men. J Bone Miner Res 21:1871–1878PubMedCrossRef
33.
Zurück zum Zitat Martin A, David V, Malaval L et al (2007) Opposite effects of leptin on bone metabolism: a dose-dependent balance related to energy intake and insulin-like growth factor-1 pathway. Endocrinology 148:3419–3425PubMedCrossRef Martin A, David V, Malaval L et al (2007) Opposite effects of leptin on bone metabolism: a dose-dependent balance related to energy intake and insulin-like growth factor-1 pathway. Endocrinology 148:3419–3425PubMedCrossRef
34.
Zurück zum Zitat Considine RV, Considine EL, Williams CJ et al (1996) The hypothalamic leptin receptor in humans: identification of incidental sequence polymorphisms and absence of the db/db mouse and fa/fa rat mutations. Diabetes 45:992–994PubMedCrossRef Considine RV, Considine EL, Williams CJ et al (1996) The hypothalamic leptin receptor in humans: identification of incidental sequence polymorphisms and absence of the db/db mouse and fa/fa rat mutations. Diabetes 45:992–994PubMedCrossRef
35.
Zurück zum Zitat Matsuoka N, Ogawa Y, Hosoda K et al (1997) Human leptin receptor gene in obese Japanese subjects: evidence against either obesity-causing mutations or association of sequence variants with obesity. Diabetologia 40:1204–1210PubMedCrossRef Matsuoka N, Ogawa Y, Hosoda K et al (1997) Human leptin receptor gene in obese Japanese subjects: evidence against either obesity-causing mutations or association of sequence variants with obesity. Diabetologia 40:1204–1210PubMedCrossRef
36.
Zurück zum Zitat Chung WK, Power-Kehoe L, Chua M et al (1997) Exonic and intronic sequence variation in the human leptin receptor gene (LEPR). Diabetes 46:1509–1511PubMed Chung WK, Power-Kehoe L, Chua M et al (1997) Exonic and intronic sequence variation in the human leptin receptor gene (LEPR). Diabetes 46:1509–1511PubMed
37.
Zurück zum Zitat Quinton ND, Lee AJ, Ross RJ, Eastell R, Blakemore AI (2001) A single nucleotide polymorphism (SNP) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian women. Hum Genet 108:233–236PubMedCrossRef Quinton ND, Lee AJ, Ross RJ, Eastell R, Blakemore AI (2001) A single nucleotide polymorphism (SNP) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian women. Hum Genet 108:233–236PubMedCrossRef
38.
Zurück zum Zitat Chagnon YC, Wilmore JH, Borecki IB et al (2000) Associations between the leptin receptor gene and adiposity in middle-aged Caucasian males from the HERITAGE family study. J Clin Endocrinol Metab 85:29–34PubMedCrossRef Chagnon YC, Wilmore JH, Borecki IB et al (2000) Associations between the leptin receptor gene and adiposity in middle-aged Caucasian males from the HERITAGE family study. J Clin Endocrinol Metab 85:29–34PubMedCrossRef
39.
Zurück zum Zitat Fairbrother UL, Tanko LB, Walley AJ et al (2007) Leptin receptor genotype at Gln223Arg is associated with body composition, BMD, and vertebral fracture in postmenopausal Danish women. J Bone Miner Res 22:544–550PubMedCrossRef Fairbrother UL, Tanko LB, Walley AJ et al (2007) Leptin receptor genotype at Gln223Arg is associated with body composition, BMD, and vertebral fracture in postmenopausal Danish women. J Bone Miner Res 22:544–550PubMedCrossRef
40.
Zurück zum Zitat Koh JM, Kim DJ, Hong JS et al (2002) Estrogen receptor alpha gene polymorphisms Pvu II and Xba I influence association between leptin receptor gene polymorphism (Gln223Arg) and bone mineral density in young men. Eur J Endocrinol 147:777–783PubMedCrossRef Koh JM, Kim DJ, Hong JS et al (2002) Estrogen receptor alpha gene polymorphisms Pvu II and Xba I influence association between leptin receptor gene polymorphism (Gln223Arg) and bone mineral density in young men. Eur J Endocrinol 147:777–783PubMedCrossRef
41.
Zurück zum Zitat Crabbe P, Goemaere S, Zmierczak H et al (2006) Are serum leptin and the Gln223Arg polymorphism of the leptin receptor determinants of bone homeostasis in elderly men? Eur J Endocrinol 154:707–714PubMedCrossRef Crabbe P, Goemaere S, Zmierczak H et al (2006) Are serum leptin and the Gln223Arg polymorphism of the leptin receptor determinants of bone homeostasis in elderly men? Eur J Endocrinol 154:707–714PubMedCrossRef
42.
Zurück zum Zitat Richert L, Chevalley T, Manen D et al (2007) Bone mass in prepubertal boys is associated with a Gln223Arg amino acid substitution in the leptin receptor. J Clin Endocrinol Metab Richert L, Chevalley T, Manen D et al (2007) Bone mass in prepubertal boys is associated with a Gln223Arg amino acid substitution in the leptin receptor. J Clin Endocrinol Metab
43.
Zurück zum Zitat Thomas T (2004) The complex effects of leptin on bone metabolism through multiple pathways. Curr Opin Pharmacol 4:295–300PubMedCrossRef Thomas T (2004) The complex effects of leptin on bone metabolism through multiple pathways. Curr Opin Pharmacol 4:295–300PubMedCrossRef
44.
Zurück zum Zitat Holloway WR, Collier FM, Aitken CJ et al (2002) Leptin inhibits osteoclast generation. J Bone Miner Res 17:200–209PubMedCrossRef Holloway WR, Collier FM, Aitken CJ et al (2002) Leptin inhibits osteoclast generation. J Bone Miner Res 17:200–209PubMedCrossRef
45.
Zurück zum Zitat Burguera B, Hofbauer L, Thomas T et al (2001) Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology 142:3546–3553PubMedCrossRef Burguera B, Hofbauer L, Thomas T et al (2001) Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology 142:3546–3553PubMedCrossRef
46.
Zurück zum Zitat Thomas T, Gori F, Khosla S et al (1999) Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140:1630–1638PubMedCrossRef Thomas T, Gori F, Khosla S et al (1999) Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140:1630–1638PubMedCrossRef
47.
Zurück zum Zitat Hess R, Pino A, Rios S, Fernandez M, Rodriguez J (2004) High affinity leptin receptors are present in human mesenchymal stem cells (MSCs) derived from control and osteoporotic donors. J Cellular Biochem 94:50–57CrossRef Hess R, Pino A, Rios S, Fernandez M, Rodriguez J (2004) High affinity leptin receptors are present in human mesenchymal stem cells (MSCs) derived from control and osteoporotic donors. J Cellular Biochem 94:50–57CrossRef
48.
Zurück zum Zitat Laharrague P, Larrouy D, Fontanilles AM (1998) High expression of leptin by human bone marrow adipocytes in primary culture. FASEB J 12:747–752PubMed Laharrague P, Larrouy D, Fontanilles AM (1998) High expression of leptin by human bone marrow adipocytes in primary culture. FASEB J 12:747–752PubMed
49.
Zurück zum Zitat Kim G, Hong J, Kim S et al (2003) Leptin induces apoptosis via ERK/cPLA2/Cytochrome c pathway in human bone marrow stromal cells. J Biol Chem 278:21920–21929PubMedCrossRef Kim G, Hong J, Kim S et al (2003) Leptin induces apoptosis via ERK/cPLA2/Cytochrome c pathway in human bone marrow stromal cells. J Biol Chem 278:21920–21929PubMedCrossRef
50.
Zurück zum Zitat Hamrick M, Della-Fera MA, Hartzell D, Choi Y-H, Baile CA (2007) Intrahypothalamic injections of leptin increase adipocyte apoptosis in peripheral fat pad and in bone marrow. Cell Tissue Res 327:133–141PubMedCrossRef Hamrick M, Della-Fera MA, Hartzell D, Choi Y-H, Baile CA (2007) Intrahypothalamic injections of leptin increase adipocyte apoptosis in peripheral fat pad and in bone marrow. Cell Tissue Res 327:133–141PubMedCrossRef
51.
Zurück zum Zitat Meunier P, Aaron J, Edouard C, Vignon G (1971) Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. Clin Orthop Rel Res 80:147–154CrossRef Meunier P, Aaron J, Edouard C, Vignon G (1971) Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. Clin Orthop Rel Res 80:147–154CrossRef
52.
Zurück zum Zitat Kajkenova O, Lecka-Czernik F, Gubrij I et al (1997) Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia. J Bone Miner Res 12:1772–1779PubMedCrossRef Kajkenova O, Lecka-Czernik F, Gubrij I et al (1997) Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia. J Bone Miner Res 12:1772–1779PubMedCrossRef
53.
Zurück zum Zitat Justesen J, Stenderup K, Ebbesen E et al (2001) Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2:165–171PubMedCrossRef Justesen J, Stenderup K, Ebbesen E et al (2001) Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. Biogerontology 2:165–171PubMedCrossRef
54.
Zurück zum Zitat Verma S, Rajaratnam J, Denton J et al (2002) Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J Clin Pathol 55:693–698PubMedCrossRef Verma S, Rajaratnam J, Denton J et al (2002) Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J Clin Pathol 55:693–698PubMedCrossRef
55.
Zurück zum Zitat Lazarenko O, Rzonca S, Hogue W et al (2007) Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148:2669–2680PubMedCrossRef Lazarenko O, Rzonca S, Hogue W et al (2007) Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148:2669–2680PubMedCrossRef
56.
Zurück zum Zitat Schwartz A, Sellmeyer D, Vittinghoff D et al (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349–3354PubMedCrossRef Schwartz A, Sellmeyer D, Vittinghoff D et al (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349–3354PubMedCrossRef
57.
Zurück zum Zitat Elmquist JK, Maratos-Flier E, Saper CB et al (1998) Unraveling the central nervous system pathways underlying responses to leptin. Nat Neurosci 1:445–450PubMedCrossRef Elmquist JK, Maratos-Flier E, Saper CB et al (1998) Unraveling the central nervous system pathways underlying responses to leptin. Nat Neurosci 1:445–450PubMedCrossRef
58.
Zurück zum Zitat Ducy P, Amling M, Takeda S, Priemel M, Schilling A, Beil F, Shen J, Vinson C, Rueger J, Karsenty G (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197–207PubMedCrossRef Ducy P, Amling M, Takeda S, Priemel M, Schilling A, Beil F, Shen J, Vinson C, Rueger J, Karsenty G (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197–207PubMedCrossRef
59.
Zurück zum Zitat Elefteriou F, Ahn JD, Takeda S et al (2005) Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434:514–520PubMedCrossRef Elefteriou F, Ahn JD, Takeda S et al (2005) Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434:514–520PubMedCrossRef
60.
Zurück zum Zitat Hamrick MW, Pennington C, Newton D, Xie D, Isales C (2004) Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone 34:376–383PubMedCrossRef Hamrick MW, Pennington C, Newton D, Xie D, Isales C (2004) Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone 34:376–383PubMedCrossRef
61.
Zurück zum Zitat Baldock PA, Allison S, McDonald MM et al (2006) Hypothalamic regulation of cortical bone mass: opposing activity of Y2 receptor and leptin pathways. J Bone Miner Res 21:1600–1607PubMedCrossRef Baldock PA, Allison S, McDonald MM et al (2006) Hypothalamic regulation of cortical bone mass: opposing activity of Y2 receptor and leptin pathways. J Bone Miner Res 21:1600–1607PubMedCrossRef
62.
Zurück zum Zitat Kellenberger S, Muller K, Richener H, Bilbe G (1998) Formoterol and isoproterenol induce c-fos gene expression in osteoblast-like cells by activating beta2-adrenergic receptors. Bone 22:471–478PubMedCrossRef Kellenberger S, Muller K, Richener H, Bilbe G (1998) Formoterol and isoproterenol induce c-fos gene expression in osteoblast-like cells by activating beta2-adrenergic receptors. Bone 22:471–478PubMedCrossRef
63.
Zurück zum Zitat Moore RE, Smith CK, II, Bailey CS, Voelkel EF, Tashjian AH, Jr (1993) Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. Bone Miner 23:301–315PubMedCrossRef Moore RE, Smith CK, II, Bailey CS, Voelkel EF, Tashjian AH, Jr (1993) Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. Bone Miner 23:301–315PubMedCrossRef
64.
Zurück zum Zitat Suzuki A, Guicheux J, Palmer G et al (2002) Evidence for a role of p38 MAP kinase in expression of alkaline phosphatase during osteoblastic cell differentiation. Bone 30:91–98PubMedCrossRef Suzuki A, Guicheux J, Palmer G et al (2002) Evidence for a role of p38 MAP kinase in expression of alkaline phosphatase during osteoblastic cell differentiation. Bone 30:91–98PubMedCrossRef
65.
Zurück zum Zitat Suzuki A, Palmer G, Bonjour JP, Caverzasio J (1998) Catecholamines stimulate the proliferation and alkaline phosphatase activity of MC3T3-E1 osteoblast-like cells. Bone 23:197–203PubMedCrossRef Suzuki A, Palmer G, Bonjour JP, Caverzasio J (1998) Catecholamines stimulate the proliferation and alkaline phosphatase activity of MC3T3-E1 osteoblast-like cells. Bone 23:197–203PubMedCrossRef
66.
Zurück zum Zitat Takeda S, Elefteriou F, Levasseur R et al (2002) Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305–317PubMedCrossRef Takeda S, Elefteriou F, Levasseur R et al (2002) Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305–317PubMedCrossRef
67.
Zurück zum Zitat Togari A, Arai M, Mizutani S, Mizutani S, Koshihara Y, Nagatsu T (1997) Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neurosci Lett 233:125–128PubMedCrossRef Togari A, Arai M, Mizutani S, Mizutani S, Koshihara Y, Nagatsu T (1997) Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neurosci Lett 233:125–128PubMedCrossRef
68.
Zurück zum Zitat Arai M, Nagasawa T, Koshihara Y, Yamamoto S, Togari A (2003) Effects of beta-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells. Biochim Biophys Acta 1640:137–142PubMedCrossRef Arai M, Nagasawa T, Koshihara Y, Yamamoto S, Togari A (2003) Effects of beta-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells. Biochim Biophys Acta 1640:137–142PubMedCrossRef
69.
Zurück zum Zitat Togari A, Mogi M, Arai M, Yamamoto S, Koshihara Y (2000) Expression of mRNA for axon guidance molecules, such as semaphorin-III, netrins and neurotrophins, in human osteoblasts and osteoclasts. Brain Res 878:204–209PubMedCrossRef Togari A, Mogi M, Arai M, Yamamoto S, Koshihara Y (2000) Expression of mRNA for axon guidance molecules, such as semaphorin-III, netrins and neurotrophins, in human osteoblasts and osteoclasts. Brain Res 878:204–209PubMedCrossRef
70.
Zurück zum Zitat Takeuchi T, Tsuboi T, Arai M, Togari A (2001) Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. Biochem Pharmacol 61:579–586PubMedCrossRef Takeuchi T, Tsuboi T, Arai M, Togari A (2001) Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. Biochem Pharmacol 61:579–586PubMedCrossRef
71.
Zurück zum Zitat Glatt V, Canalis E, Stadmeyer L, M Bouxsein (2007) Age-related changes in trabecular architecture differ in female and male C57BL/6J mice. J Bone Miner Res 22:1197–1207PubMedCrossRef Glatt V, Canalis E, Stadmeyer L, M Bouxsein (2007) Age-related changes in trabecular architecture differ in female and male C57BL/6J mice. J Bone Miner Res 22:1197–1207PubMedCrossRef
72.
Zurück zum Zitat Cao J, Venton L, Sakata T, Halloran BP (2003) Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. J Bone Miner Res 18:270–277PubMedCrossRef Cao J, Venton L, Sakata T, Halloran BP (2003) Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. J Bone Miner Res 18:270–277PubMedCrossRef
73.
Zurück zum Zitat Pierroz D, Muzzin P, Glatt V et al (2004) β1β2-adrenergic receptor ko mice have decreased total body and cortical bone mass despite increased trabecular bone number. J Bone Miner Res 19(supp 1):1121 Pierroz D, Muzzin P, Glatt V et al (2004) β1β2-adrenergic receptor ko mice have decreased total body and cortical bone mass despite increased trabecular bone number. J Bone Miner Res 19(supp 1):1121
74.
Zurück zum Zitat Fu L, Patel M, Bradley A et al (2005) The molecular clock mediates leptin-regulated bone formation. Cell 122:803–815PubMedCrossRef Fu L, Patel M, Bradley A et al (2005) The molecular clock mediates leptin-regulated bone formation. Cell 122:803–815PubMedCrossRef
75.
Zurück zum Zitat Turek F, Joshu C, Kohsaka A et al (2005) Obesity and metabolic syndrome in circadian Clock mutant mice. Science 308:1043–1045PubMedCrossRef Turek F, Joshu C, Kohsaka A et al (2005) Obesity and metabolic syndrome in circadian Clock mutant mice. Science 308:1043–1045PubMedCrossRef
76.
Zurück zum Zitat Gomez-Abellan P, Hernandez-Morante, Lujan J et al (2007) Clock genes are implicated in the human metabolic syndrome. Int J Obesity 1–8 Gomez-Abellan P, Hernandez-Morante, Lujan J et al (2007) Clock genes are implicated in the human metabolic syndrome. Int J Obesity 1–8
77.
Zurück zum Zitat Pierroz D, Bouxsein M, Cavat F et al (2006) Synergistic effects of adrenergic blockade and intermittent parathyroid hormone on bone in ovariectomized mice. Bone 39:260–267PubMedCrossRef Pierroz D, Bouxsein M, Cavat F et al (2006) Synergistic effects of adrenergic blockade and intermittent parathyroid hormone on bone in ovariectomized mice. Bone 39:260–267PubMedCrossRef
78.
Zurück zum Zitat Bonnet N, Beaupied H, Vico L et al (2007) Combined effects of exercise and propranolol on bone tissue in ovariectomized rats. J Bone Miner Res 22:578–588PubMedCrossRef Bonnet N, Beaupied H, Vico L et al (2007) Combined effects of exercise and propranolol on bone tissue in ovariectomized rats. J Bone Miner Res 22:578–588PubMedCrossRef
79.
Zurück zum Zitat Bonnet N, Laroche N, Vico L et al (2006) Dose effects of propranolol on cancellous and cortical bone in ovariectomized adult rats. J Pharmacol Exp Ther 318:1118–1127PubMedCrossRef Bonnet N, Laroche N, Vico L et al (2006) Dose effects of propranolol on cancellous and cortical bone in ovariectomized adult rats. J Pharmacol Exp Ther 318:1118–1127PubMedCrossRef
80.
Zurück zum Zitat Pierroz D, Bouxsein ML, Muzzin P et al (2005) Bone loss following ovariectomy is maintained in absence of adrenergic receptor ß1 and ß2 signaling. J Bone Miner Res 20(Suppl.1):S277 Pierroz D, Bouxsein ML, Muzzin P et al (2005) Bone loss following ovariectomy is maintained in absence of adrenergic receptor ß1 and ß2 signaling. J Bone Miner Res 20(Suppl.1):S277
81.
Zurück zum Zitat Dhillon H, Glatt V, Ferrari S, Bouxsein ML (2004) β-Adrenergic receptor KO mice have increased bone mass and strength but are not protected from ovariectomy-induced bone loss. J Bone Miner Res 19(Suppl.1):S32 Dhillon H, Glatt V, Ferrari S, Bouxsein ML (2004) β-Adrenergic receptor KO mice have increased bone mass and strength but are not protected from ovariectomy-induced bone loss. J Bone Miner Res 19(Suppl.1):S32
82.
Zurück zum Zitat Marenzana M, De Souza RL, Chenu C (2007) Blockade of beta-adrenergic signaling does not influence the bone mechano-adaptive response in mice. Bone 41:206–215PubMedCrossRef Marenzana M, De Souza RL, Chenu C (2007) Blockade of beta-adrenergic signaling does not influence the bone mechano-adaptive response in mice. Bone 41:206–215PubMedCrossRef
83.
Zurück zum Zitat Zeman RJ, Hirschman A, Hirschman ML et al (1991) Clenbuterol, a beta 2-receptor agonist, reduces net bone loss in denervated hindlimbs. Am J Physiol 261(2 Pt 1):E285–E289PubMed Zeman RJ, Hirschman A, Hirschman ML et al (1991) Clenbuterol, a beta 2-receptor agonist, reduces net bone loss in denervated hindlimbs. Am J Physiol 261(2 Pt 1):E285–E289PubMed
84.
Zurück zum Zitat Baker JG, Hall IP, Hill SJ (2003) Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 64:1357–1369PubMedCrossRef Baker JG, Hall IP, Hill SJ (2003) Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 64:1357–1369PubMedCrossRef
85.
Zurück zum Zitat Pierroz D, Baldock PA, Bouxsein ML, Ferrari S (2006) Low cortical bone mass in mice lacking beta 1 and beta 2 adrenergic receptors is associated with low bone formation and circulating IGF-1. J Bone Min Res 21(Suppl. 1):S26 Pierroz D, Baldock PA, Bouxsein ML, Ferrari S (2006) Low cortical bone mass in mice lacking beta 1 and beta 2 adrenergic receptors is associated with low bone formation and circulating IGF-1. J Bone Min Res 21(Suppl. 1):S26
86.
Zurück zum Zitat Levasseur R, Dargent-Molina P, Sabatier JP et al (2005) Beta-blocker use, bone mineral density, and fracture risk in older women: results from the Epidemiologie de l’Osteoporose prospective study. J Am Geriatr Soc 53:550–552PubMedCrossRef Levasseur R, Dargent-Molina P, Sabatier JP et al (2005) Beta-blocker use, bone mineral density, and fracture risk in older women: results from the Epidemiologie de l’Osteoporose prospective study. J Am Geriatr Soc 53:550–552PubMedCrossRef
87.
Zurück zum Zitat Pasco JA, Henry MJ, Sanders KM et al (2004) Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong osteoporosis study. J Bone Miner Res 19:19–24PubMedCrossRef Pasco JA, Henry MJ, Sanders KM et al (2004) Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong osteoporosis study. J Bone Miner Res 19:19–24PubMedCrossRef
88.
Zurück zum Zitat Reid IR, Gamble GD, Grey AB, et al (2005) Beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 20:613–618PubMedCrossRef Reid IR, Gamble GD, Grey AB, et al (2005) Beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 20:613–618PubMedCrossRef
89.
Zurück zum Zitat Reid IR, Lucas J, Wattie D et al (2005) Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab 90:5212–5216PubMedCrossRef Reid IR, Lucas J, Wattie D et al (2005) Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab 90:5212–5216PubMedCrossRef
90.
Zurück zum Zitat Rejnmark L, Vestergaard P, Kassem M et al (2004) Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int 75:365–372PubMedCrossRef Rejnmark L, Vestergaard P, Kassem M et al (2004) Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int 75:365–372PubMedCrossRef
91.
Zurück zum Zitat Rejnmark L, Vestergaard P, Mosekilde L (2006) Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 24:581–589PubMedCrossRef Rejnmark L, Vestergaard P, Mosekilde L (2006) Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 24:581–589PubMedCrossRef
92.
Zurück zum Zitat Schlienger RG, Kraenzlin ME, Jick SS et al (2004) Use of beta-blockers and risk fractures. JAMA 292:1326–1332PubMedCrossRef Schlienger RG, Kraenzlin ME, Jick SS et al (2004) Use of beta-blockers and risk fractures. JAMA 292:1326–1332PubMedCrossRef
93.
Zurück zum Zitat Khosla S (2002) Leptin-central or peripheral to the regulation of bone metabolism? Endocrinology 143:4161–4164PubMedCrossRef Khosla S (2002) Leptin-central or peripheral to the regulation of bone metabolism? Endocrinology 143:4161–4164PubMedCrossRef
94.
Zurück zum Zitat Hamrick MW (2004) Leptin, bone mass, & the thrifty phenotype. J Bone Miner Res 19:1607–1611PubMedCrossRef Hamrick MW (2004) Leptin, bone mass, & the thrifty phenotype. J Bone Miner Res 19:1607–1611PubMedCrossRef
95.
Zurück zum Zitat Baldock P, Allison S, McDonald M et al (2006) Hypothalamic regulation of cortical bone mass: opposing activity of Y2 receptor and leptin pathways. J Bone Miner Res 21:1600–1607PubMedCrossRef Baldock P, Allison S, McDonald M et al (2006) Hypothalamic regulation of cortical bone mass: opposing activity of Y2 receptor and leptin pathways. J Bone Miner Res 21:1600–1607PubMedCrossRef
Metadaten
Titel
Leptin and the sympathetic connection of fat to bone
verfasst von
M. W. Hamrick
S. L. Ferrari
Publikationsdatum
01.07.2008
Verlag
Springer-Verlag
Erschienen in
Osteoporosis International / Ausgabe 7/2008
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-007-0487-9

Weitere Artikel der Ausgabe 7/2008

Osteoporosis International 7/2008 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.